

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
AbbVie (Mirvetuximab soravtansine)	All Wales Therapeutics and Toxicology Centre
 Patient/carer groups Black Health Agency for Equality Cancer 52 Cancer Black Care Cancer Equality Eve Appeal Go Girls Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation
OvacomeOvarian Cancer ActionSouth Asian Health FoundationSpecialised Healthcare Alliance	 Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Target Ovarian Cancer Tenovus Cancer Care The Robin Cancer Trust Wellbeing of Women Women's Health Concern 	 Possible comparator companies Accord (paclitaxel) Alliance Healthcare (paclitaxel) Baxter (pegylated liposomal doxorubicin hydrochloride (PLDH) monotherapy)
 Healthcare professional groups Association of Anaesthetists Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland British Association of Surgical Oncology British Geriatrics Society British Gynaecological Cancer Society 	 Bristol-Myers Squibb Pharmaceuticals Ltd (paclitaxel) Fresenius Kabi Ltd (paclitaxel) Pfizer Ltd (paclitaxel) Seacross Pharmaceuticals Ltd (paclitaxel) Relevant research groups Cochrane Gynaecological Cancer Group

Provisional stakeholder list for the evaluation of mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Oncology Pharmacy Association British Psychosocial Oncology Society British Society of Urogynaecology Cancer Research UK National Forum of Gynaecological Oncology Nurses Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Obstetricians and Gynaecologists Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Genomics England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

Issue date: November 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.